ArticleScientific reports2014
Actively targeted in vivo multiplex detection of intrinsic cancer biomarkers using biocompatible SERS nanotags.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 199 citations in OpenAlex.
- Multiplexed Integrin Detection and Cancer Cell Classification Using Multicolor Gap-Enhanced Gold Nanorods and Machine Learning Algorithm.Nanomaterials (Basel, Switzerland) · 2025Article
- SERS-guided photodynamic therapy: pioneering strategies in advanced cancer diagnosis and treatment.Discover nano · 2025Review
- A Permeabilization Workflow To Enable Specific Multiplexed Profiling Using SERS Nanoparticles.ACS applied materials & interfaces · 2025Article
- In vivo surface-enhanced Raman scattering techniques: nanoprobes, instrumentation, and applications.Light, science & applications · 2025Review
- Review
- Advancements in SERS: Revolutionizing Biomedical Analysis and Applications.Nanotheranostics · 2025Review
- Nanoplasmonics biosensors: At the frontiers of biomedical diagnostics.Trends in analytical chemistry : TRAC · 2024Article
- The evolution of immune profiling: will there be a role for nanoparticles?Nanoscale horizons · 2024Review
- Review
- Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines.Journal of nanobiotechnology · 2024Article
- SERS in 3D cell models: a powerful tool in cancer research.Chemical Society reviews · 2024Review
- Advanced Tuneable Micronanoplatforms for Sensitive and Selective Multiplexed Spectroscopic Sensing via Electro-Hydrodynamic Surface Molecular Lithography.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Research progress on the mechanism of exosome-mediated virus infection.Frontiers in cellular and infection microbiology · 2024Review
- Review
- Nano-biosensor for SARS-CoV-2/COVID-19 detection: methods, mechanism and interface design.RSC advances · 2023Review
- Recent Trends in SERS-Based Plasmonic Sensors for Disease Diagnostics, Biomolecules Detection, and Machine Learning Techniques.Biosensors · 2023Review
- Highly Excretable Gold Supraclusters for TranslatableACS nano · 2023Article
- AuNP-based biosensors for the diagnosis of pathogenic human coronaviruses: COVID-19 pandemic developments.Analytical and bioanalytical chemistry · 2022Review
- Exploring Sensitive Label-Free Multiplex Analysis with Raman-Coded Microbeads and SERS-Coded Reporters.Biosensors · 2022Article
- Advances in Surface Enhanced Raman Spectroscopy forNanotheranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surface-enhanced Raman scattering (SERS) technique is becoming highly popular for multiplex biosensing due to the 'fingerprint' Raman spectra from every molecule. As a proof-of-concept, we demonstrated the actively targeted multiplex in vitro and in vivo detection of three intrinsic cancer biomarkers - EGFR, CD44 and TGFβRII in a breast cancer model using three multiplexing capable, biocompatible SERS nanoparticles/nanotags. Intra-tumorally injected antibody conjugated nanotags specifically targeting the three biomarkers exhibited maximum signal at 6 hours and no detectable signal at 72 hours. However, nanotags without antibodies showed no detectable signal after 6 hours. This difference could be due to the specific binding of the bioconjugated nanotags to the receptors on the cell surface. Thus, this study establishes SERS nanotags as an ultrasensitive nanoprobe for the multiplex detection of biomarkers and opens up its potential application in monitoring tumor progression and therapy and development into a theranostic probe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.